The efficacy of autologous platelet rich plasma vs homologous platelet lysate in patients with early knee osteoarthritis

Abstract

Introduction: Recently the idea of "Orthobiologics" leads to development of less invasive procedures and accelerated treatments which enhances functional recovery of musculoskeletal disorders. The desired therapeutic effect of autologous platelet rich plasma is facilitated by the ability of IL-1-Ra to limit the destructive inflammatory intra-articular (IA) actions of IL-1β. Objectives: To evaluate the efficacy and functional outcome of autologous PRP injection and homologous platelet lysate to reduce pain, improve joint function and enhance quality of life in patients with early knee osteoarthritis and to investigate the advantages and disadvantages of PRP and homologous platelet lysate. Material and Methods: A total of 121 cases of early osteoarthritis were equally divided into PRP and homologous platelet lysate group. Each patient in both groups has been given ultrasound guided PRP and homologous platelet lysate on day 0, at the end of 4 weeks and 8 weeks and all the patients were followed for up to one year. Treatment outcome measures were assessed at each visit using VAS and WOMAC scores. Results: A statistically significant improvement is observed with VAS and WOMAC score in knee osteoarthritis patients over 12 months with greater advantages over homologous platelet lysate. The overall reduction of pain and enhanced joint function was observed within 1 week, 3 months and 12 months after the initial injection. Conclusion:Homologous platelet lysate has the potential to offer chondroprotective and molecular approach in treating pain and functionality in patients with mild and moderate knee osteoarthritis with greater advantages over autologous platelet rich plasma.

Cellular therapy: shafts of light emerging for COVID-19

“…The challenge here is the technique of lyophilisation and immunogenicity (22,37). The advantage in platelet lysate is the quantification of bioactive molecules present in it (46). However, it's a long way to go for validating the dose and administration techniques in various diseases.…”